Skip to main content
Clinical Trials/NCT04786145
NCT04786145
Unknown
Not Applicable

Cryoneurolysis Outcome on Pain Experience (COPE) in Patients With Low-back Pain - a Single-blinded Randomized Controlled Trial

University of Aarhus1 site in 1 country120 target enrollmentFebruary 15, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Low-back Pain
Sponsor
University of Aarhus
Enrollment
120
Locations
1
Primary Endpoint
The effect of the intervention, assessed by Patient Global Impression of Change (PGIC) at 4 weeks follow-up
Last Updated
3 years ago

Overview

Brief Summary

This study will provide information on the effectiveness of cryoneurolysis for patients with facet joint pain syndrome, and help to establish whether cryoneurolysis should be implemented in clinical practice for this patient population.

Detailed Description

Background: Low-back pain, including facet joint pain, accounts for up to 20 percent of all sick leaves in Denmark; among these are patients with facet joint pain syndrome. A proposed treatment option is cryoneurolysis. This study aims to investigate the effect of cryoneurolysis in lumbar facet joint pain syndrome Methods: A single-center randomized controlled trial (RCT) is performed including 120 participants with chronic facet joint pain syndrome, referred to the Department of Neurosurgery, Aarhus University Hospital. Eligible patients receive a diagnostic anesthetic block, where a reduction of pain intensity \>50 % on a numerical rating scale (NRS) is required to be enrolled. Participants are randomized into three groups to undergo either one treatment of cryoneurolysis, radiofrequency ablation or placebo. Fluoroscopy and sensory stimulation is used to identify the intended target nerve prior to administrating the above-mentioned treatments. All groups receive physiotherapy for 6 weeks, starting 4 weeks after treatment. The primary outcome is a reduction in low-back pain intensity and an impression of change in pain after intervention (Patient Global Impression of Change (PGIC)) at 4 weeks follow-up, prior to physiotherapy. Secondary outcomes are quality of life (EQ-5D, SF-36) and level of function (Oswestry Disability Index), psychological perception of pain (Pain Catastrophizing Scale) and depression status (Major Depression Inventory). Data will be assessed at baseline (T0), randomization (T1), day one (T2), 4 weeks (T3), 3 (T4), 6 (T5) and 12 months

Registry
clinicaltrials.gov
Start Date
February 15, 2020
End Date
October 1, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Low-back pain from facet joint syndrom (facet joint pain) \> 3 months' duration with or without neuropathic pain component.
  • Low-back pain on Numeric Rating Scale ≥ 4

Exclusion Criteria

  • Presence of nerve root or spinal canal compression; signs of inflammatory or erosive processes in the spine verified on magnetic resonance imaging (MRI).
  • Neurological deficits i.e. symptoms of nerve root compression; tingling, numbness, weakness/ paresis, and reflex loss in the lower extremities.
  • Major co-morbidity.
  • Anti-thrombotic or anti-platelet treatment which cannot be paused for a week.
  • Active malignancies.
  • Chronic inflammatory disease.
  • Known severe psychiatric disease. Patients with mild and well-treated depression and anxiety are not excluded.

Outcomes

Primary Outcomes

The effect of the intervention, assessed by Patient Global Impression of Change (PGIC) at 4 weeks follow-up

Time Frame: 4 weeks

The Patient Global Impression of Change (PGIC) is a 7-point patient self-reporting scale of overall improvement after treatment ranging from 1) very much improved, 2) much improved, 3) minimally improved, 4) no change, 5) minimally worse, 6) much worse, or 7) very much worse

Secondary Outcomes

  • Change in the Numeric Rating Scale (NRS-11) from baseline to day one, four weeks, three, six and 12 months follow-up(1-12 months)
  • Change from baseline to 12 months follow-up for change in Major Depression Inventory (MDI) and the Short Form (36) Health Survey (SF-36)(1-12 months)
  • Change in Patient Global Impression of Change (PGIC) at day one, three, six and 12 months follow-up.(1-12 months)
  • Change in the Pain Catastrophizing Scale (PCS) at baseline, four weeks, three, six and 12 months follow-up(1-12 months)
  • Change from baseline to six and 12 months follow-up in the Oswestry Disability Index (ODI).(1-12 months)
  • Change from baseline to six and 12 months follow-up in the European Quality of Life - 5 Dimensions (EQ5D)(1-12 months)

Study Sites (1)

Loading locations...

Similar Trials